Merck reports Q2 2026 adjusted loss per share of 13 cents, beating the 23 cents loss estimate, with sales of $16.61B exceeding guidance and Keytruda revenue reaching $8.37B; full-year adjusted EPS guidance narrowed to $2.66–$2.76 from $5.04–$5.16 due to $9B and $5.7B charges related to Cidara and Terns acquisitions.
FirstSquawk08/04, 05:43 PM
- Adj Loss/SHR 13C
- Est Loss/SHR 23C
- Sales $16.61B
- Est $16.35B
Figures as quoted by FirstSquawk